These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 27071050)

  • 1. How to Assess Fibrinogen Levels and Fibrin Clot Properties in Clinical Practice?
    Undas A
    Semin Thromb Hemost; 2016 Jun; 42(4):381-8. PubMed ID: 27071050
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma fibrin clot structure and thromboembolism: clinical implications.
    Ząbczyk M; Undas A
    Pol Arch Intern Med; 2017 Dec; 127(12):873-881. PubMed ID: 29225327
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Additive roles of platelets and fibrinogen in whole-blood fibrin clot formation upon dilution as assessed by thromboelastometry.
    Ninivaggi M; Feijge MA; Baaten CC; Kuiper GJ; Marcus MA; Ten Cate H; Lancé MD; Heemskerk JW; van der Meijden PE
    Thromb Haemost; 2014 Mar; 111(3):447-57. PubMed ID: 24258426
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Laboratory Testing for Fibrinogen Disorders: From Routine Investigations to Research Studies.
    Undas A
    Semin Thromb Hemost; 2024 Jun; ():. PubMed ID: 38889802
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alterations in Fibrin Structure in Patients with Liver Diseases.
    Lisman T; Ariëns RA
    Semin Thromb Hemost; 2016 Jun; 42(4):389-96. PubMed ID: 27071046
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The impact of hematocrit on fibrin clot formation assessed by rotational thromboelastometry.
    Ogawa S; Szlam F; Bolliger D; Nishimura T; Chen EP; Tanaka KA
    Anesth Analg; 2012 Jul; 115(1):16-21. PubMed ID: 22467887
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A new insight into retinal vein occlusion pathogenesis.
    Karska-Basta I; Kubicka-Trzaska A; Pogrzebielski A; Romanowska-Dixon B
    Klin Oczna; 2013; 115(4):269-74. PubMed ID: 24908915
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Unfavorably Altered Fibrin Clot Properties in Patients with Eosinophilic Granulomatosis with Polyangiitis (Churg-Strauss Syndrome): Association with Thrombin Generation and Eosinophilia.
    Mastalerz L; Celińska-Lӧwenhoff M; Krawiec P; Batko B; Tłustochowicz W; Undas A
    PLoS One; 2015; 10(11):e0142167. PubMed ID: 26540111
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thyroid dysfunction and fibrin network structure: a mechanism for increased thrombotic risk in hyperthyroid individuals.
    Hooper JM; Stuijver DJ; Orme SM; van Zaane B; Hess K; Gerdes VE; Phoenix F; Rice P; Smith KA; Alzahrani SH; Standeven KF; Ajjan RA
    J Clin Endocrinol Metab; 2012 May; 97(5):1463-73. PubMed ID: 22378816
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antithrombotic medications and their impact on fibrin clot structure and function.
    Undas A; Zabczyk M
    J Physiol Pharmacol; 2018 Aug; 69(4):. PubMed ID: 30415236
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fibrin clot properties in women heterozygous for factor V Leiden mutation: effects of oral contraceptives.
    Krzek M; Ciesla-Dul M; Zabczyk M; Undas A
    Thromb Res; 2012 Oct; 130(4):e216-21. PubMed ID: 22940058
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased plasma clot permeability and susceptibility to lysis are associated with heavy menstrual bleeding of unknown cause: a case-control study.
    Szczepaniak P; Zabczyk M; Undas A
    PLoS One; 2015; 10(4):e0125069. PubMed ID: 25909989
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Altered plasma fibrin clot properties are associated with in-stent thrombosis.
    Undas A; Zalewski J; Krochin M; Siudak Z; Sadowski M; Pregowski J; Dudek D; Janion M; Witkowski A; Zmudka K
    Arterioscler Thromb Vasc Biol; 2010 Feb; 30(2):276-82. PubMed ID: 19910643
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fibrinogen and fibrin: scaffold proteins in hemostasis.
    Lord ST
    Curr Opin Hematol; 2007 May; 14(3):236-41. PubMed ID: 17414213
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advancing Thrombosis Research: A Novel Device for Measuring Clot Permeability.
    Landi E; Mugnaini M; Vatansever T; Fort A; Vignoli V; Giurranna E; Argento FR; Fini E; Emmi G; Fiorillo C; Becatti M
    Sensors (Basel); 2024 Jun; 24(12):. PubMed ID: 38931548
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fibrin, γ'-fibrinogen, and transclot pressure gradient control hemostatic clot growth during human blood flow over a collagen/tissue factor wound.
    Muthard RW; Welsh JD; Brass LF; Diamond SL
    Arterioscler Thromb Vasc Biol; 2015 Mar; 35(3):645-54. PubMed ID: 25614284
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fibrinogen.
    Stang LJ; Mitchell LG
    Methods Mol Biol; 2013; 992():181-92. PubMed ID: 23546714
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Altered plasma fibrin clot properties in essential thrombocythemia.
    Małecki R; Gacka M; Kuliszkiewicz-Janus M; Jakobsche-Policht U; Kwiatkowski J; Adamiec R; Undas A
    Platelets; 2016; 27(2):110-6. PubMed ID: 25989112
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Functional impact of oxidative posttranslational modifications on fibrinogen and fibrin clots.
    Martinez M; Weisel JW; Ischiropoulos H
    Free Radic Biol Med; 2013 Dec; 65():411-418. PubMed ID: 23851017
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of oxidation-modified fibrinogen on the formation and lysis of fibrin clot in the plasma.
    Piryazev AP; Aseichev AV; Azizova OA
    Bull Exp Biol Med; 2009 Dec; 148(6):881-5. PubMed ID: 21116496
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.